Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

4:01pm EDT
Change (% chg)

$-0.22 (-0.26%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for LLY.N


Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company's products are sold in approximately 120 countries. The Company's human pharmaceutical business segment... (more)


Beta: 0.23
Market Cap(Mil.): $93,106.32
Shares Outstanding(Mil.): 1,108.54
Dividend: 0.50
Yield (%): 2.38


  LLY.N Industry Sector
P/E (TTM): 43.60 34.64 35.23
EPS (TTM): 1.93 -- --
ROI: 7.44 15.37 14.82
ROE: 12.61 15.91 15.68
Search Stocks

BRIEF-Adocia and Lilly initiate phase 1b study evaluating BioChaperone Lispro

* Adocia and Eli Lilly and Company initiate a phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy

06 Oct 2015

BRIEF-Adocia and Lilly initiate a new phase 1b study of BioChaperone Lispro

* Adocia and Eli Lilly and Company initiate a new phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes

30 Sep 2015

Lilly, Incyte arthritis drug found better than common treatment

- Eli Lilly and Co and Incyte Corp said their experimental drug was found to be more effective in treating rheumatoid arthritis than a commonly prescribed medicine, in a late-stage study.

29 Sep 2015

NORDIC STOCKS - Factors to watch on Sept 18

The following stocks may be affected by newspaper reports and other factors on Friday:

18 Sep 2015

CORRECTED-BRIEF- Eli Lilly and Co says EMPA-REG OUTCOME met its primary endpoint

Aug 20 - Eli Lilly and Co : * Jardiance demonstrated cardiovascular (cv) risk reduction in people with type 2 diabetes at high risk for cv events * Says empa-reg outcome met its primary endpoint * Says empa-reg outcome demonstrated superiority of jardiance, when added to standard of care, in cv risk reduction * Source text for Eikon * Further company coverage

20 Aug 2015

Eli Lilly shifts Alzheimer-drug study to USC

- Pharmaceutical giant Eli Lilly announced Tuesday it will shift the funding for clinical trials of an early-stage Alzheimer's treatment from the University of California San Diego to the University of Southern California. The study of solanezumab is a large part of the Alzheimer's Disease Cooperative Study, a $100 million, 70-member consortium that has been headquartered at UCSD since its inception in 1991.

06 Aug 2015

Lilly sales inch up on demand for animal health, new drugs

July 23 - Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business.

23 Jul 2015

Britain's Immunocore raises $320 mln in record financing round

DUBLIN, July 16 - Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly & Co, Malin and Woodford Investment Management.

16 Jul 2015

BRIEF-British biotech firm Immunocore to raise $320 mln in finance

* British biotech firm immunocore says secures $320 million in Europe's largest private life sciences financing

16 Jul 2015

Lilly cancer drug improves survival, raises blood clot risk: FDA

WASHINGTON - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots, according to a preliminary review by the U.S. Food and Drug Administration.

07 Jul 2015


Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks